Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626777 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TSHRCASP1SMN1; SMN2KDM4E | |
| SCHEMBL2704261 | 0.82 | ALDH1A1 (0.58) | ALDH1A1TSHRCASP1SMN1; SMN2POLB | |
| SCHEMBL9667415 | 0.82 | CYP3A4 (0.50) | ALDH1A1TSHRCASP1SMN1; SMN2POLB | |
| SCHEMBL25108258 | 0.81 | ABL1 (0.42) | ALDH1A1SMN1; SMN2MAPTRAB9AKDM4E | |
| SCHEMBL25107416 | 0.80 | LMNA (0.57) | ALDH1A1TSHRPOLBMAPTL3MBTL1 | |
| SCHEMBL28002678 | 0.79 | POLB (0.50) | ALDH1A1TSHRPOLBMAPTHPGD | |
| SCHEMBL22406930 | 0.79 | MAPT (0.47) | SMN1; SMN2MAPTRAB9AMAPK1MEN1 | |
| SCHEMBL608814 | 0.78 | ABL1 (0.68) | ALDH1A1TSHRCASP1SMN1; SMN2POLB | |
| SCHEMBL481450 | 0.78 | TSHR (0.64) | ALDH1A1TSHRCASP1SMN1; SMN2POLB | |
| SCHEMBL17466101 | 0.78 | ATM (0.54) | ALDH1A1TSHRCASP1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-219996583-U | Sampling detection device in preparation process of 2- (2, 4-dichlorophenyl) methyl acrylate | 安徽云帆药业有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116969900-A | Preparation process of 2- (2, 4-dichlorophenyl) -3- (1-H, 1,2, 4-triazolyl) propanol | 安徽云帆药业有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-219996583-U | Sampling detection device in preparation process of 2- (2, 4-dichlorophenyl) methyl acrylate | 安徽云帆药业有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-219996583-U | Sampling detection device in preparation process of 2- (2, 4-dichlorophenyl) methyl acrylate | 安徽云帆药业有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-219996583-U | Sampling detection device in preparation process of 2- (2, 4-dichlorophenyl) methyl acrylate | 安徽云帆药业有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116969900-A | Preparation process of 2- (2, 4-dichlorophenyl) -3- (1-H, 1,2, 4-triazolyl) propanol | 安徽云帆药业有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969900-A | Preparation process of 2- (2, 4-dichlorophenyl) -3- (1-H, 1,2, 4-triazolyl) propanol | 安徽云帆药业有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-2734526-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-9221832-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-06-12 | — | — | US | disclosed |
| EP-2734526-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013014587-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-31 | — | — | WO | disclosed |
| EP-0099165-A1 | Triazole and imidazole compounds, process for their preparation and their use as fungicides and plant growth regulators, and intermediates for their synthesis | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | ALDH1A1 2258/4885TSHR 332/4885CASP1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.